- Home
- Publications
- Publication Search
- Publication Details
Title
The journey of CAR-T therapy in hematological malignancies
Authors
Keywords
-
Journal
Molecular Cancer
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-10-08
DOI
10.1186/s12943-022-01663-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid manufacturing of non-activated potent CAR T cells
- (2022) Saba Ghassemi et al. Nature Biomedical Engineering
- BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy
- (2022) Barry Paul et al. DRUGS
- Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
- (2022) Pritha Agarwalla et al. NATURE BIOTECHNOLOGY
- Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
- (2022) Sattva S. Neelapu et al. NATURE MEDICINE
- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
- (2022) Adam D. Cohen et al. Blood Cancer Journal
- Nanobody-based CAR-T cells for cancer immunotherapy
- (2022) Pouya Safarzadeh Kozani et al. Biomarker Research
- Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
- (2022) Saad Zafar Usmani et al. JOURNAL OF CLINICAL ONCOLOGY
- Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
- (2022) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- CRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study
- (2022) Pouya Safarzadeh Kozani et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails
- (2022) Brian R. Shy et al. NATURE BIOTECHNOLOGY
- Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma
- (2021) Agrima Mian et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical experience of CAR T cells for multiple myeloma
- (2021) Gary L. Simmons et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
- (2021) Ken Ogasawara et al. CLINICAL PHARMACOKINETICS
- The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: A multicenter interim analysis.
- (2021) Hui Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.
- (2021) Stephen J. Schuster et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
- (2021) Bijal D Shah et al. LANCET
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
- (2021) Jay Y. Spiegel et al. NATURE MEDICINE
- Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
- (2021) Tanya Siddiqi et al. BLOOD
- A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
- (2021) Ian W. Flinn et al. BLOOD
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
- (2021) Caron A Jacobson et al. LANCET ONCOLOGY
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- (2021) Frederick L. Locke et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies
- (2020) Jeffrey Teoh et al. BLOOD
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction
- (2020) Nathan Singh et al. Cancer Discovery
- Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
- (2020) Rajat Bansal et al. BLOOD REVIEWS
- Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.
- (2020) Alison R. Sehgal et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling
- (2020) Benjamin I. Philipson et al. Science Signaling
- Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR
- (2020) Dana Stenger et al. BLOOD
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
- (2020) Guido Ghilardi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
- (2020) Zhitao Ying et al. Cancer Medicine
- Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel
- (2019) Andreas Viardot et al. Cancer Management and Research
- IL-15-mediated reduction of mTORC1 activity preserves the stem cell memory phenotype of CAR-T cells and confers superior antitumor activity
- (2019) Darya Alizadeh et al. Cancer Immunology Research
- Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
- (2019) Chuang Sun et al. Oncotarget
- An immunoproteomic approach to characterize the CAR interactome and signalosome
- (2019) Maria C. Ramello et al. Science Signaling
- Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
- (2019) Mohamed-Reda Benmebarek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
- (2019) Sophia Stock et al. INTERNATIONAL JOURNAL OF CANCER
- CAR-T efficacy: is conditioning the key?
- (2019) Sattva S. Neelapu BLOOD
- Clinical lessons learned from the first leg of the CAR T cell journey
- (2019) Robbie G. Majzner et al. NATURE MEDICINE
- Evidence for interaction of the NLRP3 inflammasome and Bruton’s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta
- (2019) Brooke Benner et al. OncoImmunology
- Clinical Response in Relapsed/Refractory (R/R) B-NHL Treated with the CD19-Directed CAR T-Cell Product JWCAR029
- (2019) Zhitao Ying et al. BLOOD
- Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
- (2019) Xiao Han et al. Journal of Hematology & Oncology
- Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity
- (2019) Olli Dufva et al. BLOOD
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)
- (2018) L. Drgona et al. CLINICAL MICROBIOLOGY AND INFECTION
- A guide to manufacturing CAR T cell therapies
- (2018) Philipp Vormittag et al. CURRENT OPINION IN BIOTECHNOLOGY
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- (2018) Kevin M. Friedman et al. HUMAN GENE THERAPY
- PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
- (2018) Wenting Zheng et al. LEUKEMIA
- A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects
- (2018) Yuki Kagoya et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- B cell adaptor for PI3-kinase (BCAP) modulates CD8+ effector and memory T cell differentiation
- (2018) Mark D. Singh et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
- (2017) Lingyan Ping et al. Oncotarget
- PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells
- (2017) Jacob S. Bowers et al. Frontiers in Immunology
- Global Manufacturing of CAR T Cell Therapy
- (2017) Bruce L. Levine et al. Molecular Therapy-Methods & Clinical Development
- Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
- (2017) Michiru Nishita et al. Scientific Reports
- Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy
- (2016) Oladapo O. Yeku et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
- (2016) Partow Kebriaei et al. JOURNAL OF CLINICAL INVESTIGATION
- Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
- (2016) Eloah Rabello Suarez et al. Oncotarget
- Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia
- (2016) Carolina Cubillos-Zapata et al. OncoImmunology
- Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
- (2015) S. E. M. Herman et al. CLINICAL CANCER RESEARCH
- BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
- (2015) S-S Chen et al. LEUKEMIA
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- (2014) S. Guedan et al. BLOOD
- Nanobodies: Natural Single-Domain Antibodies
- (2013) Serge Muyldermans Annual Review of Biochemistry
- Simplified process for the production of anti–CD19-CAR–engineered T cells
- (2013) Barbara Tumaini et al. CYTOTHERAPY
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
- (2012) Markus Chmielewski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
- (2011) D.-G. Song et al. BLOOD
- IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
- (2011) M. Chmielewski et al. CANCER RESEARCH
- A human memory T cell subset with stem cell–like properties
- (2011) Luca Gattinoni et al. NATURE MEDICINE
- Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies
- (2011) Jiahui Yang et al. PLoS One
- In vivo targeting of B-cell lymphoma with glycan ligands of CD22
- (2010) W. C. Chen et al. BLOOD
- Large-scale bioreactor expansion of tumor-infiltrating lymphocytes
- (2010) Arian Sadeghi et al. JOURNAL OF IMMUNOLOGICAL METHODS
- The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3 Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex
- (2010) J. S. Bridgeman et al. JOURNAL OF IMMUNOLOGY
- IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response
- (2008) M. P. Rubinstein et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started